{
    "Rank": 369,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT03159572",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "JGOG3025"
                },
                "SecondaryIdInfoList": {
                    "SecondaryIdInfo": [
                        {
                            "SecondaryId": "UMIN000026303",
                            "SecondaryIdType": "Other Identifier",
                            "SecondaryIdDomain": "UMIN-CTR"
                        }
                    ]
                },
                "Organization": {
                    "OrgFullName": "Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan",
                    "OrgClass": "OTHER"
                },
                "BriefTitle": "Homologous Recombination Inquiry Through Ovarian Malignancy Investigations",
                "OfficialTitle": "Homologous Recombination Inquiry Through Ovarian Malignancy Investigations",
                "Acronym": "HITOMI"
            },
            "StatusModule": {
                "StatusVerifiedDate": "January 2023",
                "OverallStatus": "Completed",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "March 28, 2017",
                    "StartDateType": "Actual"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "February 16, 2022",
                    "PrimaryCompletionDateType": "Actual"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "February 16, 2022",
                    "CompletionDateType": "Actual"
                },
                "StudyFirstSubmitDate": "May 17, 2017",
                "StudyFirstSubmitQCDate": "May 17, 2017",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "May 18, 2017",
                    "StudyFirstPostDateType": "Actual"
                },
                "LastUpdateSubmitDate": "January 19, 2023",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "January 20, 2023",
                    "LastUpdatePostDateType": "Actual"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyType": "Sponsor"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan",
                    "LeadSponsorClass": "OTHER"
                },
                "CollaboratorList": {
                    "Collaborator": [
                        {
                            "CollaboratorName": "Department of Obstetrics and Gynecology, School of Medicine, Niigata University",
                            "CollaboratorClass": "UNKNOWN"
                        },
                        {
                            "CollaboratorName": "Japanese Gynecologic Oncology Group (JGOG)",
                            "CollaboratorClass": "UNKNOWN"
                        },
                        {
                            "CollaboratorName": "Tohoku Medical Megabank Organization(ToMMo)",
                            "CollaboratorClass": "UNKNOWN"
                        }
                    ]
                }
            },
            "OversightModule": {
                "OversightHasDMC": "Yes",
                "IsFDARegulatedDrug": "No",
                "IsFDARegulatedDevice": "No"
            },
            "DescriptionModule": {
                "BriefSummary": "To investigate the frequency and clinical significance of Homologous Recombination Deficiency (HRD) in Japanese patients with ovarian cancer (including Fallopian tube cancer and primary peritoneal cancer).",
                "DetailedDescription": "In this study, investigators plan to clarify the frequency of Homologous Recombination Deficiency (HRD) in Japanese patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer).\n\nAnd investigators will also investigate whether HRD-positive ovarian cancer patients show the clinical characteristics of highly platinum-sensitivity and good prognosis, comparing to HRD-negative ovarian cancer patients.\n\nIn addition, it is planned to investigate any association between Progression Free Survival (PFS) / Platinum-Sensitivity and germline mutation in Breast Cancer Susceptibility Gene (BRCA1/2 gene) in ovarian cancer patients who can provide the patients' gBRCA1/2 gene information for this study."
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Ovarian Cancer",
                        "Fallopian Tube Cancer",
                        "Primary Peritoneal Cancer"
                    ]
                },
                "KeywordList": {
                    "Keyword": [
                        "Ovarian cancer",
                        "Fallopian tube cancer",
                        "Primary peritoneal cancer",
                        "Germline Breast Cancer Susceptibility Gene (BRCA1/2 gene)",
                        "Homologous Recombination Deficiency (HRD)"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Observational",
                "PatientRegistry": "No",
                "DesignInfo": {
                    "DesignObservationalModelList": {
                        "DesignObservationalModel": [
                            "Cohort"
                        ]
                    },
                    "DesignTimePerspectiveList": {
                        "DesignTimePerspective": [
                            "Retrospective"
                        ]
                    }
                },
                "BioSpec": {
                    "BioSpecRetention": "Samples With DNA",
                    "BioSpecDescription": "tumor tissue"
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "996",
                    "EnrollmentType": "Actual"
                }
            },
            "ArmsInterventionsModule": {
                "ArmGroupList": {
                    "ArmGroup": [
                        {
                            "ArmGroupLabel": "Ovarian cancer group",
                            "ArmGroupDescription": "Patients who are diagnosed with ovarian cancer and have a plan of surgery."
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "Frequency of HRD in patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer)",
                            "PrimaryOutcomeDescription": "When all tumor samples are stored at ToMMo after the term of registration, DNA are extracted from frozen tumor tissue. These extracted tumor DNA, after confirmed at inspection body that it has constant qualities, are examined for HRD by DNA target sequencing.",
                            "PrimaryOutcomeTimeFrame": "17 months"
                        }
                    ]
                },
                "SecondaryOutcomeList": {
                    "SecondaryOutcome": [
                        {
                            "SecondaryOutcomeMeasure": "Association between Progression Free Survival (PFS) / Response Rate and HRD in patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer)",
                            "SecondaryOutcomeDescription": "PFS is calculated from registration date to the date diagnosed as progression or the date of death from any cause, whichever comes earlier. Response rate(RR) is determined the rate of patients who are evaluated of best overall response as CR(complete response) or PR(partial response) from those with measurable disease (based on Guidelines to Evaluate the Response to Treatment in Solid Tumors, RESIST).\n\nAssociation between PFS/RR and HRD which is clarified as primary outcome is assessed.",
                            "SecondaryOutcomeTimeFrame": "48 months"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Association between Progression Free Survival (PFS) / Response Rate and germline mutation in BRCA1/2 gene in patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer)",
                            "SecondaryOutcomeDescription": "PFS is calculated from registration date diagnosed as having progression or the date of death from any cause, whichever comes earlier. Response rate(RR) is determined the rate of patients who are evaluated of best overall response as CR(complete response) or PR(partial response) from those with measurable disease (based on Guidelines to Evaluate the Response to Treatment in Solid Tumors, RESIST).\n\nAssociation between PFS/RR and gBRCA1/2 gene information from patients who can provide their gBCRA1/2 gene information with their informed consent, is evaluated.",
                            "SecondaryOutcomeTimeFrame": "48 months"
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "Inclusion Criteria:\n\nPatients who can approve informed consent and sign it. Patients who show their will to participate in this study and can sign the informed consent forms by themselves.\nPatients who are clinically diagnosed as having ovarian cancer and can provide written informed consent before the surgery.\nPatients who can provide tumor tissue specimens. (except ascites cytology and cell block specimens)\nPatients who are 20 years old and over at the enrollment.\nPatients with ECOG Performance status (PS): 0-2.\n\nExclusion Criteria:\n\nPatients with active concomitant malignancy* except breast cancer.\n\n*Includes synchronous multiple cancer and metachronous multiple cancer with less than 5 years of disease free survival. However, excludes skin basal cell carcinoma, skin squamous cell carcinoma, and any other curable lesions with local therapy such as carcinoma in situ or intramucosal carcinoma.\n\nPatients who are diagnosed as any other acute/chronic, physically/mentally severe diseases and judged by the primary physician as inappropriate to enroll this study because of safety reasons or any influence to study outcomes.\nAny other cases that are inappropriate to enroll this study, judged by study principal investigator.",
                "HealthyVolunteers": "No",
                "Gender": "Female",
                "MinimumAge": "20 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult",
                        "Older Adult"
                    ]
                },
                "StudyPopulation": "Adult ovarian cancer patients who provided written informed consent including providing tumor tissue specimens before surgery.",
                "SamplingMethod": "Non-Probability Sample"
            },
            "ContactsLocationsModule": {
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "Takayuki Enomoto, MD, Ph.D",
                            "OverallOfficialAffiliation": "Department of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences",
                            "OverallOfficialRole": "Study Chair"
                        }
                    ]
                },
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "Niigata University Graduate School of Medical and Dental Sciences",
                            "LocationCity": "Niigata city",
                            "LocationState": "Niigata Prefecture",
                            "LocationZip": "951-8510",
                            "LocationCountry": "Japan"
                        }
                    ]
                }
            },
            "IPDSharingStatementModule": {
                "IPDSharing": "Undecided"
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000010051",
                            "ConditionMeshTerm": "Ovarian Neoplasms"
                        },
                        {
                            "ConditionMeshId": "D000005185",
                            "ConditionMeshTerm": "Fallopian Tube Neoplasms"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000009369",
                            "ConditionAncestorTerm": "Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000004701",
                            "ConditionAncestorTerm": "Endocrine Gland Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000009371",
                            "ConditionAncestorTerm": "Neoplasms by Site"
                        },
                        {
                            "ConditionAncestorId": "D000010049",
                            "ConditionAncestorTerm": "Ovarian Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000000291",
                            "ConditionAncestorTerm": "Adnexal Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000005831",
                            "ConditionAncestorTerm": "Genital Diseases, Female"
                        },
                        {
                            "ConditionAncestorId": "D000052776",
                            "ConditionAncestorTerm": "Female Urogenital Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000005261",
                            "ConditionAncestorTerm": "Female Urogenital Diseases and Pregnancy Complications"
                        },
                        {
                            "ConditionAncestorId": "D000091642",
                            "ConditionAncestorTerm": "Urogenital Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000005833",
                            "ConditionAncestorTerm": "Genital Neoplasms, Female"
                        },
                        {
                            "ConditionAncestorId": "D000014565",
                            "ConditionAncestorTerm": "Urogenital Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000091662",
                            "ConditionAncestorTerm": "Genital Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000004700",
                            "ConditionAncestorTerm": "Endocrine System Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000006058",
                            "ConditionAncestorTerm": "Gonadal Disorders"
                        },
                        {
                            "ConditionAncestorId": "D000005184",
                            "ConditionAncestorTerm": "Fallopian Tube Diseases"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M12664",
                            "ConditionBrowseLeafName": "Ovarian Neoplasms",
                            "ConditionBrowseLeafAsFound": "Ovarian Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M1704",
                            "ConditionBrowseLeafName": "Carcinoma, Ovarian Epithelial",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M4910",
                            "ConditionBrowseLeafName": "Breast Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M7070",
                            "ConditionBrowseLeafName": "Disease Susceptibility",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M8018",
                            "ConditionBrowseLeafName": "Fallopian Tube Neoplasms",
                            "ConditionBrowseLeafAsFound": "Fallopian Tube Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M7553",
                            "ConditionBrowseLeafName": "Endocrine Gland Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M12662",
                            "ConditionBrowseLeafName": "Ovarian Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M3333",
                            "ConditionBrowseLeafName": "Adnexal Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M8633",
                            "ConditionBrowseLeafName": "Genital Diseases, Female",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M2877",
                            "ConditionBrowseLeafName": "Genital Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M2876",
                            "ConditionBrowseLeafName": "Urogenital Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M26783",
                            "ConditionBrowseLeafName": "Female Urogenital Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M13817",
                            "ConditionBrowseLeafName": "Pregnancy Complications",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M8089",
                            "ConditionBrowseLeafName": "Female Urogenital Diseases and Pregnancy Complications",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M8635",
                            "ConditionBrowseLeafName": "Genital Neoplasms, Female",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M17005",
                            "ConditionBrowseLeafName": "Urogenital Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M7552",
                            "ConditionBrowseLeafName": "Endocrine System Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M8853",
                            "ConditionBrowseLeafName": "Gonadal Disorders",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M8017",
                            "ConditionBrowseLeafName": "Fallopian Tube Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "T4352",
                            "ConditionBrowseLeafName": "Ovarian Cancer",
                            "ConditionBrowseLeafAsFound": "Ovarian Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "T4354",
                            "ConditionBrowseLeafName": "Ovarian Epithelial Cancer",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "T2189",
                            "ConditionBrowseLeafName": "Fallopian Tube Cancer",
                            "ConditionBrowseLeafAsFound": "Fallopian Tube Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BXS",
                            "ConditionBrowseBranchName": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC19",
                            "ConditionBrowseBranchName": "Gland and Hormone Related Diseases"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC17",
                            "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC23",
                            "ConditionBrowseBranchName": "Symptoms and General Pathology"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "Rare",
                            "ConditionBrowseBranchName": "Rare Diseases"
                        }
                    ]
                }
            }
        }
    }
}